home / stock / crdf / crdf quote
Last: | $3.63 |
---|---|
Change Percent: | -1.6% |
Open: | $3.8 |
Close: | $3.63 |
High: | $3.84 |
Low: | $3.6 |
Volume: | 539,190 |
Last Trade Date Time: | 05/17/2024 03:00:00 am |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$3.63 | $3.8 | $3.63 | $3.84 | $3.6 | 539,190 | 05-17-2024 |
$3.74 | $3.56 | $3.74 | $3.84 | $3.54 | 498,781 | 05-16-2024 |
$3.57 | $3.59 | $3.57 | $3.75 | $3.525 | 334,072 | 05-15-2024 |
$3.58 | $3.6 | $3.58 | $3.86 | $3.545 | 844,276 | 05-14-2024 |
$3.48 | $3.39 | $3.48 | $3.55 | $3.39 | 341,899 | 05-13-2024 |
$3.39 | $3.43 | $3.39 | $3.4714 | $3.3 | 471,847 | 05-10-2024 |
$3.38 | $3.19 | $3.38 | $3.65 | $3.19 | 1,118,376 | 05-09-2024 |
$3.2 | $3.31 | $3.2 | $3.3899 | $3.16 | 484,606 | 05-08-2024 |
$3.31 | $3.44 | $3.31 | $3.47 | $3.245 | 610,337 | 05-07-2024 |
$3.46 | $3.55 | $3.46 | $3.63 | $3.11 | 1,713,965 | 05-06-2024 |
$3.52 | $3.98 | $3.52 | $4.42 | $3.12 | 2,160,660 | 05-03-2024 |
$4.48 | $4.25 | $4.48 | $4.495 | $4.0702 | 843,863 | 05-02-2024 |
$4.23 | $4.38 | $4.23 | $4.45 | $4.15 | 484,574 | 05-01-2024 |
$4.36 | $4.5 | $4.36 | $4.54 | $4.26 | 577,186 | 04-30-2024 |
$4.46 | $4.14 | $4.46 | $4.68 | $4.12 | 1,048,202 | 04-29-2024 |
$4.07 | $4.06 | $4.07 | $4.129 | $3.98 | 516,215 | 04-26-2024 |
$3.99 | $4.12 | $3.99 | $4.2 | $3.95 | 586,641 | 04-25-2024 |
$4.18 | $4.17 | $4.18 | $4.38 | $4.09 | 343,158 | 04-24-2024 |
$4.17 | $4.36 | $4.17 | $4.4197 | $4.06 | 702,309 | 04-23-2024 |
$4.36 | $4.26 | $4.36 | $4.49 | $4.25 | 462,511 | 04-22-2024 |
News, Short Squeeze, Breakout and More Instantly...
Cardiff Oncology Inc. Company Name:
CRDF Stock Symbol:
NASDAQ Market:
SAN DIEGO, May 13, 2024 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (NASDAQ:CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibit...
SAN DIEGO, May 13, 2024 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, today announced that company management will present at two upcoming investor conferences in M...